Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16401337 | 0.93 | PTGER4 (0.49) | CYP4A11CYP4F2PTGER4PTGER2PTGER3 | |
| SCHEMBL4946290 | 0.93 | PTGER4 (0.49) | CYP4A11CYP4F2PTGER4PTGER2PTGER3 | |
| SCHEMBL4940026 | 0.86 | CYP4A11 (0.49) | CYP4A11CYP4F2PTGER4PTGER2PTGER3 | |
| SCHEMBL4992221 | 0.84 | PTGER4 (0.53) | CYP4A11CYP4F2PTGER4PTGER2PTGER3 | |
| SCHEMBL19513647 | 0.84 | PTGER4 (0.53) | CYP4A11CYP4F2PTGER4PTGER2PTGER3 | |
| SCHEMBL4992213 | 0.84 | PTGER4 (0.53) | CYP4A11CYP4F2PTGER4PTGER2PTGER3 | |
| SCHEMBL4691039 | 0.83 | RAB9A (0.47) | KDM4E | |
| SCHEMBL4688520 | 0.83 | RAB9A (0.47) | KDM4E | |
| SCHEMBL5733032 | 0.81 | PTGER4 (0.50) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL4991287 | 0.80 | PTGER3 (0.57) | PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603874-B1 | G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7276531-B2 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-10-02 | — | — | US | disclosed |
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | PTGIS, PTGIR, PTGES | CYP4A11 197/4885CYP4F2 1075/4885PTGER4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.